Candel Therapeutics (NASDAQ: CADL) details viral immunotherapy R&D day

Rhea-AI Filing Summary

Candel Therapeutics reported that it will host a virtual Research and Development Day on December 5, 2025, from 11:00 a.m. to 1:45 p.m. Eastern Time. The event will provide an extensive overview of the company’s viral immunotherapy approach and its oncology-focused pipeline.

The investor presentation used for the event is being furnished as Exhibit 99.1 and will also be available in the investor relations section of the company’s website. Candel states that this information is being furnished rather than filed and will not be treated as part of its other securities law filings.

false 0001841387 0001841387 2025-12-05 2025-12-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 5, 2025

CANDEL THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-40629		52-2214851
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)
117 Kendrick St., Suite 450 Needham, MA				02494
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 916-5445

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value per share		CADL		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On December 5, 2025, Candel Therapeutics, Inc. (the “Company”) will host a virtual Research and Development (“R&D”) Day from 11:00 am – 1:45 pm ET. The event will provide an extensive overview of the Company’s viral immunotherapy approach and oncology-focused pipeline.

A copy of the presentation to be shown at the R&D Day is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. The presentation will also be available on the investor relations section of the Company’s website at https://ir.candeltx.com/. Information contained on the Company’s website is not incorporated by reference into this Current Report on Form 8-K, and you should not consider any information on, or that can be accessed from, the Company’s website as part of this Current Report on Form 8-K.

The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K are furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in any such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		R&D Day Presentation dated December 5, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Candel Therapeutics, Inc.
Date: December 5, 2025				By:		/s/ Paul Peter Tak
						Paul Peter Tak, M.D., Ph.D., FMedSci
						President and Chief Executive Officer

FAQ

What did Candel Therapeutics (CADL) disclose in this 8-K?

Candel Therapeutics disclosed that it will host a virtual Research and Development Day on December 5, 2025, providing an extensive overview of its viral immunotherapy approach and oncology-focused pipeline.

When will Candel Therapeutics (CADL) hold its virtual R&D Day and for how long?

The virtual R&D Day will take place on December 5, 2025, from 11:00 a.m. to 1:45 p.m. Eastern Time.

What topics will be covered during Candel Therapeutics’ (CADL) R&D Day?

The event will focus on an extensive overview of Candel Therapeutics’ viral immunotherapy approach and its oncology-focused pipeline.

Where can investors access the Candel Therapeutics (CADL) R&D Day presentation?

The presentation is furnished as Exhibit 99.1 and will also be available on the investor relations section of Candel Therapeutics’ website at https://ir.candeltx.com/.

Is the Candel Therapeutics (CADL) R&D Day information considered filed with the SEC?

No. The company states that the R&D Day information and Exhibit 99.1 are being furnished, not filed, and will not be incorporated by reference into other securities law filings.

What exhibits are included with this Candel Therapeutics (CADL) 8-K?

The exhibits include 99.1, the R&D Day Presentation dated December 5, 2025, and 104, the Cover Page Interactive Data File embedded within the Inline XBRL document.